---
schema_version: "secwatch.filing_event.v1"
accession: "0001575872-23-000548"
form_type: "8-K"
ticker: "SMNR"
cik: "0001913577"
company_name: "Semnur Pharmaceuticals, Inc."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T03:19:45.312374+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Denali Capital extends business combination deadline to July 11, 2023 with $825K trust deposit

## Summary
- Deposited $825,000 into trust account to extend deadline from April 11 to July 11, 2023; first of two permitted three-month extensions.
- Issued convertible promissory note to sponsor for up to $825,000; initial $412,500 drawn, balance drawable; converts at $10 per share.
- Amendment to merger agreement ensures repayment of note at closing does not reduce the minimum cash condition.
- Business combination target is Longevity Biomedical, Inc.; merger agreement entered January 25, 2023.

## SEC filing metadata
- accession: 0001575872-23-000548
- form_type: 8-K
- ticker: SMNR
- cik: 0001913577
- company_name: Semnur Pharmaceuticals, Inc.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1913577/000157587223000548/0001575872-23-000548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1913577/000157587223000548/deca-20230411.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001575872-23-000548
- JSON: https://secwatch.observer/filing/0001575872-23-000548.json
- Plain text: https://secwatch.observer/filing/0001575872-23-000548.txt

## Key facts
- Debt Financings
  Semnur Pharmaceuticals, Inc. incurred convertible notes of up to $825,000 with Denali Capital Global Investments LLC at interest equivalent to the lowest short-term Applicable Federal Rate maturing upon the earlier of (i) the closing of Denali's initial business combination and (ii) the date of the liquidation of Denali.
  - Instrument: convertible notes
  - Principal: up to $825,000
  - Counterparty: Denali Capital Global Investments LLC
  - Rate: interest equivalent to the lowest short-term Applicable Federal Rate
  - Maturity: upon the earlier of (i) the closing of Denali's initial business combination and (ii) the date of the liquidation of Denali
  - Event: incurrence
  source text: On April 11, 2023, Denali issued a convertible promissory note (the "Convertible Promissory Note") in the total principal amount of up to $825,000 to the Sponsor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1913577/000157587223000548/0001575872-23-000548-index.htm
- Material Agreements
  Semnur Pharmaceuticals, Inc. amended Amendment to and Consent under the Merger Agreement with Denali Capital Acquisition Corp., Longevity Biomedical, Inc., Denali SPAC Holdco, Inc., Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., Bradford A. Zakes, and Denali Capital Global Investments LLC (effective 2023-04-11).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Denali Capital Acquisition Corp., Longevity Biomedical, Inc., Denali SPAC Holdco, Inc., Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., Bradford A. Zakes, and Denali Capital Global Investments LLC
  - Effective: 2023-04-11
  source text: On April 11, 2023, the parties to the Merger Agreement and Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the “Sponsor”) entered into an Amendment to and Consent under the Merger Agreement (the “Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1913577/000157587223000548/0001575872-23-000548-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.